Allergen immunotherapy and asthma

Maria Angela Tosca, Roberta Olcese, Amelia Licari, Giorgio Ciprandi

Research output: Contribution to journalArticlepeer-review


Allergen immunotherapy (AIT) represents at present the unique disease-modifying treatment strategy for IgE-mediated allergic diseases. AIT can induce clinical improvement of allergic asthma, including reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Notably, the current asthma guidelines are now recommending sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy. Clinical indications of AIT, with particular reference to pediatric asthma, mechanisms of clinical and immunological tolerance to allergens, and the potential biomarkers predicting clinical response are discussed.

Original languageEnglish
Pages (from-to)46-48
Number of pages3
JournalPediatric Allergy and Immunology
Issue numberS24
Publication statusPublished - Feb 1 2020


  • allergen immunotherapy
  • allergic asthma
  • subcutaneous immunotherapy
  • sublingual immunotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Allergen immunotherapy and asthma'. Together they form a unique fingerprint.

Cite this